百日咳流行现状及免疫策略研究进展

李涛; 候立娟; 唐继海

doi:10.19837/j.cnki.ahyf.2023.06.011

PDF(816 KB)

安徽预防医学杂志 ›› 2023, Vol. 29 ›› Issue (6) : 492-496. DOI: 10.19837/j.cnki.ahyf.2023.06.011

综述

百日咳流行现状及免疫策略研究进展

李涛¹, 候立娟², 唐继海¹

作者信息 +

Research progress on the prevalence of pertussis and immunization strategies

LI Tao¹, HOU Lijuan², TANG Jihai¹

Author information +

文章历史 +

摘要

百日咳是一种由百日咳鲍特菌(Bp)引起的具有高度传染性的呼吸道疾病。白喉-破伤风-全细胞百日咳 (DTwP) 联合疫苗上市并投入使用后,全球百日咳发病率大幅下降。近年来疫苗覆盖率较高的发达国家出现“百日咳再现”,我国近年来各省份百日咳报告发病率也呈上升趋势。百日咳的再现受到百日咳鲍特菌病原学特点、疫苗种类及效果的改变、监测与诊断水平的提高等多种因素综合影响。本文综述了百日咳流行现状及全球百日咳各人群免疫策略,为我国百日咳防控提供参考依据。

Abstract

Pertussis is a highly contagious respiratory disease caused by Bordetella pertussis (Bp).After the diphtheria-tetanus-whole cell pertussis (DTwP) vaccine was introduced and put into use,the global incidence of pertussis decreased significantly.In recent years,developed countries with high vaccine coverage have seen "pertussis reappear",and the reported incidence of pertussis in various provinces in China in recent years has also shown an upward trend.The reappearance of pertussis was affected by a combination of factors,such as the pathogenic characteristics of Bordetella pertussis,the change of vaccine type and effect,and the improvement of monitoring and diagnosis level.This article reviews current situation of pertussis epidemic and the immunization strategies for various populations worldwide,providing a reference basis for the prevention and control of pertussis in China.

导出引用

李涛, 候立娟, 唐继海. 百日咳流行现状及免疫策略研究进展[J]. 安徽预防医学杂志. 2023, 29(6): 492-496 https://doi.org/10.19837/j.cnki.ahyf.2023.06.011

LI Tao, HOU Lijuan, TANG Jihai. Research progress on the prevalence of pertussis and immunization strategies[J]. Anhui Journal of Preventive Medicine. 2023, 29(6): 492-496 https://doi.org/10.19837/j.cnki.ahyf.2023.06.011

中图分类号： R516.6

参考文献

[1] Kilgore PE,Salim AM,Zervos MJ,et al.Pertussis:Microbiology,Disease,Treatment,and Prevention[J].Clin Microbiol Rev,2016,29(3):449-486.
[2] Guiso N,Meade BD,Knig C.Pertussis vaccines:The first hundred years [J].Vaccine,2019,38(5):1271-1276.
[3] Ma LH,Caulfield A,Dewan KK,et al.Pertactin-Deficient Bordetella pertussis,Vaccine-Driven Evolution,and Reemergence of Pertussis [J].Emerg Infect Dis,2021,27(6):1561-1566.
[4] 宁桂军,高源,吴丹,等.中国2011—2017年百日咳流行病学特征分析[J].中国疫苗和免疫,2018,24( 3):264-267+273.
[5] 蔡路奎,李婧妍,姬秋彦,等.2004—2019年我国百日咳报告病例流行病学特征分析[J].预防医学情报杂志,2021,37(8):1036-1043.
[6] 骆鹏,马霄.百日咳和百日咳疫苗的现状与挑战[J].中国疫苗和免疫,2019,25(3):334-339.
[7] 汪海波,罗会明,温宁,等.我国2006—2010年百日咳流行病学分析[J].中国疫苗和免疫,2012,18(3):207-210.
[8] Winter K,Zipprich J,Harriman K,et al.Risk factors associated with infant deaths from pertussis:a case-control study [J].Clin Infect Dis,2015,61(7):1099-1106.
[9] Ghorbani GR,Zahraei SM,Moosazadeh M,et al.Comparing seasonal pattern of laboratory confirmed cases ofpertussis with clinically suspected cases [J].Osong Public Health Res Perspect,2016,7(2) :131-137.
[10] Fernandes EG,Sartori AMC,de Soárez PC,et al.Challenges of interpreting epidemiologic surveillance pertussis data with changing diagnostic and immunization practices:the case of the state of Sao Paulo,Brazil [J].BMC Infect Dis,2018,18(1) :126.
[11] Van der Lee S,Stoof SP,Van Ravenhorst MB,et al.Enhanced Bordetella pertussis acquisition rate in adolescents during the 2012 epidemic in the Netherlands and evidence for prolonged antibody persistence after infection [J].Euro Surveill,2017,22(47):17-00011.
[12] Wang K,Bettiol S,Thompson MJ,et al.Symptomatic treatment of the cough in whooping cough [J].Cochrane Database Syst Rev,2014,2014(9):CD003257.
[13] Langsam D,Anis E,Haas EJ,et al.Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis [J].Vaccine,2020,38(12):2700-2706.
[14] 穆秋玥,蒋凤.2017—2019年贵州省百日咳流行病学特征[J].中国疫苗和免疫,2021,27( 1):70-73.
[15] 梁桢,胡世雄,邓志红,等.2005—2018年湖南省百日咳流行病学特征分析[J].江苏预防医学,2020,31(6):637-639.
[16] 邬辉,郑敏,吴静.2008—2019年江西省百日咳流行病学特征[J].中国疫苗和免疫,2022,28(2):150-153.
[17] 李涛,王斌冰,玄坤,等.2005—2021年安徽省百日咳流行病学特征[J].中国疫苗和免疫,2022,28(4):412-416.
[18] Yeung KHT,Duclos P,Nelson EAS,et al.An update of the global burden of pertussis in children younger than 5 years:a modelling study [J].Lancet Infect Dis,2017,17(9):74–80.
[19] Skoff TH,Hadler S,Hariri S.The Epidemiology of Nationally Reported Pertussis in the United States,2000—2016 [J].Clin Infect Dis,2019,68(10):1634-1640.
[20] Skoff TH,Martin SW.Impact of Tetanus Toxoid,Reduced Diphtheria Toxoid,and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity:A Follow-up Analysis [J].JAMA Pediatr,2016,170(5):453-458.
[21] Kilgore PE,Salim AM,Zervos MJ,et al.Pertussis:microbiology,disease,treatment,and prevention [J].Clin Microbiol Rev,2016,29(3):449-486.
[22] Choi JH,Jaime CDS,Fletcher M,et al.Improving vaccination rates in older adults and at-risk groups:focus on pertussis[J].Aging Clin Exp Res,2022,34(1):1-8.
[23] 黄海涛,李永成,高志刚,等.2010—2015 年天津市百日咳病例临床症状与误诊的特征分析[J].疾病监测,2016,31(9):791-795.
[24] 杜艳,任佳,张莉萍,等.上海市闵行区2017—2019年百日咳监测分析[J].上海预防医学,2021,33(11):1040-1045.
[25] Wendelboe AM,Hudgens MG,Poole C,et al.Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants [J].Emerg Themes Epidemiol,2007,4:15-21.
[26] 中国百日咳行动计划专家共识[J].中国疫苗和免疫,2021,27(3):317-327.
[27] Cole LE,Zhang J,Pacheco KM,et al.Immunological Distinctions between Acellular and Whole-Cell Pertussis Immunizations of Baboons Persist for at Least One Year after Acellular Vaccine Boosting [J].Vaccines (Basel),2020,8(4):729.
[28] Zerbo O,Fireman B,Klein N.Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness [J].Expert Rev Vaccines,2022,21(7):899-907.
[29] 邵杰,高晨燕,杨焕.基础免疫用组分百日咳联合疫苗临床评价的考虑[J].中国疫苗和免疫,2019,25(5):593-597.
[30] Bednarek A,Bartkowiak-Emeryk M,Klepacz R,et al.Persistence of vaccine-induced immunity in preschool children:effect of gestational age [J].Med Sci Monit,2018,23:5110-5117.
[31] Klein NP,Bartlett J,Fireman B,et al.Waning Tdap Effectiveness in Adolescents[J].Pediatrics,2016,137(3):e20153326.
[32] 李文豪,彭远舟,黄静,等.2021年深圳市学龄前儿童百日咳IgG抗体水平调查[J].中国疫苗和免疫,2021,27(6):639-642.
[33] 赵薛飞,叶硕,马瑞,等.宁波市2019年健康人群百日咳血清流行病学调查[J].中华流行病学杂志,2021,42(4):638-642.
[34] 龙秀娟,张江萍,郭俊利,等.贵州省0~7岁儿童百日咳抗体水平及影响因素研究[J].现代预防医学,2022,49(5):834-838+869.
[35] 张娟胜,王小强,张弟强,等.百日咳鲍特菌的基因多样性及分子流行病学分析[J].中华微生物学和免疫学杂志,2021,41(9):687-691.
[36] 汪丙松,张先来,李振,等.安徽省芜湖市2018年百日咳疑似病例病原菌药敏与基因型分析[J].中国热带医学,2022,22(1):37-41.
[37] 黄海涛,高志刚,丁亚兴,等.天津市百日咳监测体系介绍及其运行效果的评估[J].中国当代儿科杂志,2019,21(3):218-222.
[38] 王富明,徐倩倩,郝建华,等.2018年开封市百日咳监测病例流行病学特征分析[J].齐齐哈尔医学院学报,2020,41(20):2581-2582.
[39] Marti,Melanie.Pertussis vaccines:WHO position paper,August 2015-Recommendations [J].Vaccine,2016,34(12):1423-5.
[40] Recommended adult immunization schedule for ages 19 years or older:United States,2022[J].JAAPA,2022,35(3):1-22.
[41] Zhang Z,Pan J,Chen M,et al.Seroepidemiology of pertussis in China:A population-based,cross-sectional study [J].Vaccine,2021,39:1687-1692.
[42] Tang X,Tang T,Yan R,et al.Intention to accept pertussis vaccination among Chinese people older than age 5 [J].Hum Vaccin Immunother,2021,17(6):1686-1692.
[43] 于晓婷,谌志筠,何秋水.无细胞百日咳疫苗全球孕期接种的现状[J].微生物学免疫学进展,2020,48(3):59-65.
[44] Razzaghi H,Kahn KE,Black CL,et al.Influenza and Tdap Vaccination coverage among pregnant women-united states,April 2020 [J].MMWR Morb Mortal Wkly Rep,2020,69(39),1391-1397.
[45] Sebghati M,Khalil A.Uptake of vaccination in pregnancy[J].Best Pract Res Clin Obstet Gynaecol,2021,8(76):53-65.
[46] Boulet SL,Chamberlain AT,Biswas HH,et al.Trends in Infant Pertussis Hospitalizations in the United States,2009—2017[J].JAMA,2019,322(21),2134-2136.
[47] Vizzotti C,Juarez MV,Bergel E,et al.Impact of a maternal immunization program against pertussis in a developing country[J].Vaccine,2016,34(50),6223-6228.
[48] Langsam D,Anis E,Haas EJ,et al.Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis [J].Vaccine,2020,38:2700-2706.